Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer

Annalisa Altimari, Antonia D Errico Grigioni, Elisa Benedettini, Elena Gabusi, Riccardo Schiavina, Antonio Martinelli, Antonio Maria Morselli-Labate, Giuseppe Martorana, Walter Franco Grigioni, Michelangelo Fiorentino

Research output: Contribution to journalArticlepeer-review


To analyze the potential diagnostic relevance of free plasma DNA (FPDNA), we enrolled 64 patients with localized prostate cancer (CaP). FPDNA was quantified by real-time polymerase chain reaction assessment of the HTERT gene in blood samples from 64 patients with CaP and 45 healthy males. Methylation of the GSTP1 gene was used to confirm the neoplastic origin of FPDNA in selected cases. The mean ± SD levels of FPDNA were higher in patients with CaP (15.4 ± 10.9 ng/mL) than in control subjects (5.5 ± 3.5 ng/mL; P <.001). By using the best cutoff value, the sensitivity of the test was 80%, the specificity was 82%, the area under the receiver operating characteristic curve, 0.881. High FPDNA values were significantly associated with pathologic T3 stage (P = .035). Methylation of the GSTP1 gene was found in 4 (25%) of 16 FPDNA samples and 15 (94%) of 16 tissue samples. Quantification of FPDNA discriminates between patients with CaP and healthy subjects and correlates with pathologic tumor stage. FPDNA is a candidate biomarker for early diagnosis and monitoring of CaP.

Original languageEnglish
Pages (from-to)756-762
Number of pages7
JournalAmerican Journal of Clinical Pathology
Issue number5
Publication statusPublished - May 2008


  • Blood tumor markers
  • DNA methylation
  • Free plasma DNA
  • Prostate cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer'. Together they form a unique fingerprint.

Cite this